AKERS BIOSCIENCES, INC. Fundamentals Datasheet and Stock Analysis


Akers Biosciences, Inc. develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company's product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives. The Company's primary focus is the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company's main products include a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body.

  • Current Price:
  • Industry:
     Health Care
  • Sector:
     Health Care
  • ISIN:
  • Market Sector:
  • Main Indices:
  • Country of register:
     Great Britain
  • Currency:
  • Shares in Issue:
  • Market Cap:
  • Date Listed:
Operation Breakdown
Geographical - by origin (turnover)
Product (turnover)


Activity Data Not Available

Company Information

CEO: John J. Gormally  Non-Executive Director: Christopher C Schreiber Bill J White  Acting Chairman: Richard C Tarbox  

Composite Ranking: 
Historic EPS Ranking: 
Forecast EPS Ranking: 
Price Relative Strength: 
Industry Strength: 
SMR Ranking: 
ROCE Ranking: 
Mkt Accumulation/Dist: 
Unbroken Annual EPS: 
Unbroken Interim EPS: 
PEG Current Ranking: 
PEG Forecast Ranking: 
PE Current Ranking: 
PE Forecast Ranking: 
Margin Current Ranking: 
Margin Forecast Ranking: 
Add Indicator


Takes the average of data over a period of time, and migrates the period across the data series one data point at a time. This formula smooths a data series and makes analysing volatile data easier.
Operating Profit/(loss)$m(1.13)(3.85)(2.74)(1.81)(3.20)(9.68)(3.33)(5.05)$m0.00
Profit Before Tax$m(1.20)(3.88)(2.73)(1.53)(3.13)(9.58)(3.30)(5.81)$m0.00
Profit After Tax$m(0.92)(3.58)(2.56)(1.53)(3.14)(9.31)(3.30)(5.81)$m0.00
Profit After Tax (from discontinued operations)$m0.$m0.00
Overall Profit for the Period$m0.00(3.58)(2.56)(1.53)(3.14)(9.31)(3.30)(5.81)$m0.00
EPS Growth%
Earnings Per Share¢(156.00)(312.00)(224.00)(95.62)(66.23)(181.00)(61.00)(61.00)p0.00
Op. Cash Flow P/S¢(34.90)(45.65)0.42(1.71)(0.82)(1.00)(0.77)(0.54)$0.00
Cash Flow P/S Grth%
Net Cash Flow P/S¢$0.00
Capital Exp P/S$$0.00
Tax Rate%
P/E Ratiox0.
P/E Growth$$0.00
Turnover Per Share$61.6236.0331.570.$0.00
Pre-Tax Profit / Share$(24.29)(78.35)(55.00)$0.00
Operating Margin%
Mkt Cap$m0.0028.24178.46407.01214.0979.99152.9214.12$m0.00
Dividend Per Share¢
DPS Growth%
Dividend Yield%
Dividend Coverx0.
Shareholder Funds$m6.456.173.084.1214.816.603.399.11$m0.00
Net Borrowings$m0.00(1.19)(0.63)(0.10)(0.46)(0.40)(0.07)(0.44)$m0.00
Net Assets$m6.456.173.304.1214.816.603.399.11$m0.00
Net Assets P/S$$0.00
Latest Forecast
Div Yield0.0%0.0%
Div Cover0.0%0.0%
Op Margin-128.5%0.0%
Director Deals
Traded Action Notifier Price Amount Value
24-May-16BuyJohn J. Gormally362.25 1,131Ū,174.26
24-May-16BuyJohn J. Gormally362.25 1,131Ū,165.75
24-May-16BuyJohn J. Gormally362.25 1,131Ū,161.88
24-May-16BuyJohn J. Gormally362.25 1,131Ū,150.92
24-May-16BuyJohn J. Gormally362.25 1,131Ū,146.74
24-May-16BuyJohn J. Gormally362.25 1,131Ū,146.38
24-May-16BuyJohn J. Gormally362.25 1,131Ū,145.84
24-May-16BuyJohn J. Gormally362.25 1,131Ū,145.66
24-May-16BuyJohn J. Gormally362.25 1,131Ū,145.30
24-May-16BuyJohn J. Gormally362.25 1,131Ū,144.39
First PagePrev PageNext Page  Rows per page
94m    Major: 6%    Director: 0%
Notifier Holding Value
John J. Gormally2,500ș.50
  Rows per page
Gearing & Cover
News Title Date Time Source
Directorate Change - Form 8-K Filing13-Sep-1807:00RNS
2nd Quarter & H1 2018 Results15-Aug-1807:00RNS
Holding(s) in Company27-Jul-1815:00RNS
Mailing of 2017 Annual Report26-Jul-1807:00RNS
Issue of Equity20-Jul-1815:05RNS
Correction: Issue of Equity20-Jul-1815:00RNS
Independent Sales Representative Agreements - PIFA18-Jul-1812:00RNS-R
1st Quarter 2018 Results16-Jul-1807:03RNS
Final Results 2017 (Restated)16-Jul-1807:02RNS
3rd Quarter 2017 Results (Restated)16-Jul-1807:01RNS
First PagePrev PageNext Page  Rows per page
Broker Opinion
Date Broker Name Rec Price Old Price Target New Price Target Broker Change
07-May-14Daniel StewartBuy280.00p0.00p0.00pReiteration
  Rows per page

This functionality requires you to login

Click here to login
Or register for a new account